Black Diamond Therapeutics
(NASDAQ) BDTX
Black Diamond Therapeutics Financials at a Glance
Market Cap
$112.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$43.21M
EPS (TTM)
-$0.76
P/E Ratio
-2.60
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Price
$2.09
Volume
2,199,075.485
Open
$1.97
Price
$2.09
Volume
2,199,075.485
Open
$1.97
Previous Close
$2.08
Daily Range
$1.94 - $2.22
52-Week Range
$1.60 - $4.94
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Price
$2.09
Volume
2,199,075.485
Open
$1.97
Previous Close
$2.08
Daily Range
$1.94 - $2.22
52-Week Range
$1.60 - $4.94
Estimated Earnings Date
Aug 6, 2026
BDTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Black Diamond Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
21
CEO
Mark A. Velleca, MD, PhD
Headquarters
Cambridge, MA 02142, US
BDTX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-36.37%
Return on Capital
15.17%
Return on Assets
-32.51%
Earnings Yield
-38.46%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$112.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
57.30M
Volume
2.20M
Avg. Volume
1.72M
Financials (TTM)
Gross Profit
-$113.00K
Operating Income
-$53.27M
EBITDA
-$38.09M
Operating Cash Flow
-$34.03M
Capital Expenditure
$0.00
Free Cash Flow
-$34.03M
Cash & ST Invst.
$118.26M
Total Debt
$17.88M
Black Diamond Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$27.00K
-100.0%
Gross Margin
0.00%
N/A
Market Cap
$112.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.70M
N/A
Employees
24
N/A
Net Income
-$9.04M
-116.0%
EBITDA
-$9.01M
-115.9%
Quarterly Fundamentals
Total Cash
$118.26M
-22.4%
Total Debt
$17.88M
-17.2%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$14.09M
-21.2%
Short Term Debt
$3.79M
+2.4%
Return on Assets
-32.51%
N/A
Return on Invested Capital
-44.99%
N/A
Free Cash Flow
-$10.23M
-119.2%
Operating Cash Flow
-$10.23M
-119.2%